Meeting
2012 ASCO Annual Meeting
A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Authors
Michinori Ogura
Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Aichi, Japan
Michinori Ogura , Kiyoshi Ando , Nozomi Niitsu , Seok Jin Kim , Ken Ohmachi , Naoki Takahashi , Toshiki Uchida , Naoto Takahashi , Naokuni Uike , Hyeon Seok Eom , Yee Soo Chae , Takashi Terauchi , Ukihide Tateishi , Mitsuaki Tatsumi , Won Seog Kim , Cheolwon Suh , Kensei Tobinai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01118845
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8023)
DOI
10.1200/jco.2012.30.15_suppl.8023
Abstract #
8023
Poster Bd #
3
Abstract Disclosures
Similar Posters
First Author: Yuqin Song
Poster
2017 ASCO Annual Meeting
Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
First Author: Robert W. Chen
Poster
2015 ASCO Annual Meeting
A phase I study combining bendamustine with rituximab, etoposide and carboplatin (TREC) in patients with aggressive relapsed or refractory lymphoma.
First Author: L. Elizabeth Budde
Poster
2014 ASCO Annual Meeting
Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL.
First Author: Douglas Edward Gladstone